Hyderabad, Telangana, India, October 2025 — Cohance Lifesciences Limited has announced the appointment of Shravan Reddy J as Chief Operating Officer – CDMO, further strengthening its leadership team as it continues to expand its global footprint in the pharmaceutical and contract development manufacturing (CDMO) space.
An accomplished pharma operations leader, Shravan brings over two decades of experience in multi-site manufacturing, project management, and strategic operations across API, CRAMS, and CDMO businesses. In his new role, he will be responsible for driving operational excellence, cost optimization, compliance, and large-scale transformation programs that enhance Cohance’s global competitiveness and sustainability.
Before joining Cohance Lifesciences, Shravan served as API Operations Head at Sun Pharma, where he led multiple manufacturing sites, ensuring quality compliance and operational performance. Prior to that, he was API Manufacturing Head at Granules India Limited, leading strategic projects that strengthened process efficiency and global supply reliability.
Earlier in his career, he held leadership roles at Aurobindo Pharma, Biocon, and Piramal Pharma Solutions, where he managed end-to-end operations, cluster-level manufacturing, and technology integration initiatives. Shravan spent the formative part of his career at Dr. Reddy’s Laboratories, where he rose through several leadership roles—from Technical Services to Director and Site Head—over an 18-year tenure, building deep expertise in manufacturing excellence, regulatory compliance, and cross-functional leadership.
A graduate of SVKM’s Narsee Monjee Institute of Management Studies (NMIMS) with an MBA in Pharma Management, Shravan’s strong business acumen and operational depth position him to lead Cohance Lifesciences’ CDMO vertical into its next phase of growth and innovation.
About Cohance Lifesciences
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world. The rebranding from Suven Pharma to Cohance reflects its expanded vision and sharpened focus on collaboration and innovation.
The name Cohance captures its purpose — to Collaborate with global innovators and Enhance their molecules, helping bring transformative solutions to patients and consumers worldwide. With expertise spanning API development, formulations, and contract manufacturing, Cohance Lifesciences continues to be a trusted partner to leading global pharmaceutical companies.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
